FDA approves first RSV vaccine for at-risk adults in their 50s – CBS News
Business News
- FDA approves first RSV vaccine for at-risk adults in their 50s CBS News
- US FDA expands GSK’s RSV vaccine approval to adults aged 50 to 59 Reuters
- FDA approves GSK’s RSV vaccine for high-risk adults ages 50 to 59, expanding shot’s reach CNBC
- GSK exec lauds ‘great start’ to RSV vaccine uptake as Arexvy nabs label expansion in adults 50-59 FiercePharma
- GSK’s RSV vaccine receives expanded FDA approval STAT
Source: Business News